Taken together, our work strongly supports that C/EBP-β/AEP signaling plays a critical role in atherosclerosis pathogenesis, and blockade of AEP with its specific inhibitor may provide a powerful therapeutic agent for treating this cardiovascular disorder. Here, LGMN is linked to cardiovascular disorder.